Agenus Stock Price, News & Analysis

Agenus (NASDAQ:AGEN), an immuno-oncology company, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City.

The company's executives, Dr. Richard Goldberg (Chief Development Officer) and Dr. Robin Taylor (Chief Commercial Officer), will conduct a fireside chat on September 9, 2025, from 10:00-10:30 AM EST. They will discuss the BOT/BAL immunotherapy program, including updates on the pivotal Phase 3 BATTMAN trial in metastatic colorectal cancer, clinical data, partnerships, and upcoming milestones for H2 2025.

Agenus (Nasdaq: AGEN), a leader in immuno-oncology, has announced updated details for its virtual Stakeholder Briefing scheduled for August 27, 2025, at 4:00 p.m. ET. The webcast will feature a new virtual format and updated participation link, requiring no pre-registration.

The briefing will cover several key areas including strategic and financial overview, Zydus partnership updates, colorectal cancer (CRC) studies, BOT/BAL clinical updates, and Phase 3 BATTMAN study in metastatic CRC. Additionally, the session will spotlight MiNK Therapeutics, where Agenus holds a significant stake.

Distinguished speakers include CEO Garo H. Armen, Chief Development Officer Richard M. Goldberg, and other experts in GI oncology and cancer research. The event will conclude with a live Q&A session.

Agenus (NASDAQ: AGEN), an immuno-oncology company, will host a virtual Stakeholder Briefing on August 27, 2025, at 4:00 p.m. ET. The event will feature presentations from senior management and industry experts focusing on developments in cancer treatment.

Key topics include strategic updates on the botensilimab (BOT) and balstilimab (BAL) programs, progress following the Zydus partnership, colorectal cancer (CRC) studies including the Phase 3 BATTMAN study, and future milestones. Notable speakers include CEO Garo H. Armen, MiNK Therapeutics CEO Jennifer Buell, and newly appointed Chief Development Officer Richard M. Goldberg, along with experts from Duke University and the Canadian Cancer Trials Group.

Agenus (NASDAQ:AGEN) reported Q2 2025 financial results and significant progress in its immunotherapy program. The company's BOT/BAL combination therapy demonstrated a remarkable 42% two-year survival rate in refractory MSS colorectal cancer patients. The FDA has agreed to a streamlined two-arm Phase 3 BATTMAN trial design, set to begin in Q4 2025.

Financial highlights include Q2 2025 revenue of $25.7M and reduced net loss of $56.4M YTD. A strategic collaboration with Zydus Lifesciences is expected to close in Q3 2025, bringing $91M in capital infusion. The company also partnered with Noetik AI for biomarker development and maintains significant ownership in MiNK Therapeutics and SaponiQx.

Agenus (NASDAQ: AGEN), an immuno-oncology company, has scheduled two important upcoming events. The company will first release its Q2 2025 financial results before market opens on August 11, 2025. Following this, Agenus will host a stakeholder briefing in late August to discuss strategic plans, data milestones, and provide updates on their botensilimab (BOT) and balstilimab (BAL) development program.

Agenus (NASDAQ:AGEN) announced the acceptance of four abstracts for presentation at the ESMO Congress 2025 in Berlin, showcasing progress in their immunotherapy programs. The highlight is an oral presentation featuring emerging survival plateaus from a study of botensilimab plus balstilimab combination in 343 evaluable patients with refractory metastatic solid tumors across five tumor types.

Three additional poster presentations will showcase data from investigator-sponsored studies in cervical cancer, MSS metastatic colorectal cancer (mCRC), and non-melanoma skin cancers. These presentations demonstrate the broad potential of botensilimab and balstilimab combinations in treating difficult-to-treat cancers. The presentations will take place between October 17-21, 2025.

GSK (NYSE:GSK) has received FDA approval for a new prefilled syringe presentation of SHINGRIX, its vaccine for preventing shingles. This new format eliminates the need to reconstitute separate vials before administration, streamlining the vaccination process for healthcare professionals.

The approval is based on data showing technical comparability between the new and existing presentations. SHINGRIX remains indicated for adults aged 50 years and older, and those 18 years and older with increased shingles risk due to immunodeficiency. The CDC continues to recommend two doses of the vaccine for these populations.

The prefilled syringe presentation is currently under review by the European Medicines Agency, with filing acceptance received in January 2025.

Agenus (NASDAQ:AGEN) reported significant clinical progress for its botensilimab and balstilimab (BOT/BAL) combination therapy in microsatellite-stable metastatic colorectal cancer (MSS mCRC). The expanded study of 123 patients demonstrated a 42% two-year survival rate and 20.9-month median overall survival, with a 20% objective response rate and 16.6-month median duration of response.

The FDA has agreed to a simplified two-arm Phase 3 BATTMAN trial design, waiving the need for a BOT monotherapy arm. The company plans to initiate the global registration trial in Q4 2025. The therapy showed particularly promising results in heavily pretreated patients, with those in fourth-line or later treatment showing 19% ORR and 43% two-year survival.

Agenus (AGEN) and Noetik announced a research collaboration to develop AI-powered predictive biomarkers for their immunotherapy combination BOT/BAL. The partnership leverages Noetik's OCTO virtual cell model, a 1.5B parameter foundation model trained on data from 200M tumor and immune cells. The collaboration aims to identify which patients are most likely to respond to BOT/BAL treatment, which has already been evaluated in over 1,200 patients across nine tumor types. Noetik's technology integrates spatial proteomics, transcriptomics, pathology, and clinical data to provide comprehensive tumor microenvironment insights. The BOT/BAL combination has shown promising results in both immunotherapy-resistant tumors and various cancer types. This AI-driven approach aligns with FDA priorities for advancing precision medicine in cancer care.